亞寶藥業(600351.SH):甲鈷胺片通過仿製藥一致性評價
格隆匯12月22日丨亞寶藥業(600351.SH)公佈,近日,公司收到國家藥監局核准簽發的關於甲鈷胺片的《藥品補充申請批准通知書》(通知書編號:2021B04615),批准該藥品通過仿製藥質量和療效一致性評價。
甲鈷胺片主要用於治療周圍神經病。目前,國內共有16家公司獲得甲鈷胺片生產批文,有8家公司(包含原研公司)已通過一致性評價,根據米內網數據統計,甲鈷胺片2020年中國公立醫療市場銷售金額為19.42億元。公司甲鈷胺片2020年度銷售收入為人民幣6232.88萬元。
截止該公吿披露日,公司甲鈷胺片在仿製藥一致性評價項目上已累計投入研發費用約人民幣940.67萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.